COPD: Providing the right treatment for the right patient at the right time
Chronic Obstructive Pulmonary Disease (COPD) is a common disease associated with significant morbidity and mortality that is both preventable and treatable.
However, a major challenge in recognizing, preventing, and treating COPD is understanding its complexity. While COPD has historically been characterized as a disease defined by airflow limitation, we now understand it as a multi-component disease with many clinical phenotypes, systemic manifestations, and associated co-morbidities.
Puedes leer el artículo completo en el siguiente enlace: https://www.resmedjournal.com/article/S0954-6111(22)00306-7/fulltext#secsectitle0010
Autores:
Alvar Agusti, Nicolino Ambrosino, Felicity Blackstock, Jean Bourbeau, Richard Casaburi, Bartolome Celli, Rebecca Crouch,Roberto Dal Negro,, Michael Dreher, Christine Garvey, Daniel Gerardi, Roger Goldstein, Nicola Hanania, Anne E. Holland, Antarpreet Kaur, Suzanne Lareau, Peter K., Lindenauer, David Mannino, Barry Make, François Maltais, Jeffrey D. Marciniuk, Paula Meek, Mike Morgan, Jean-Louis, Pepin, Jane Z. Reardon, Carolyn, Rochester, Sally Singh, Martijn, A. Spruit, Michael C. Steiner, Thierry Troosters, Michele, Vitacca, Enico Clini, Jose Jardim, Linda Nici, Jonathan Raskin, Richard ZuWallack.
Noticias relacionadas
Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition. We hypothesized that the unbiased integration of different COPD lung omics using a novel multi-layer approach may unravel mechanisms associated with clinical characteristics.
Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Insight into the impact of doxycycline in therapeutic trials for COPD, emphasizing the need for careful microbiological monitoring in future interventional trials in patients with COPD
Más artículos
EPOC
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768778·Alvar Agusti, Claus F. Vogelmeier – GOLD 2024: a brief overview of key changes
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 769092·Leonardo M Fabbri et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence
COPD
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 768885·Miguel Angel Martinez-García, Alvar Agustí. – Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Recuerda que puedes acceder a varios enlaces a artículos en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imágenes obtenidas el 19/01/2023 en Canva Pro.